Submitted by Marlene Santos (marlene.bc.ufg@gmail.com) on 2016-04-19T18:36:17Z No. of bitstreams: 2 Tese - Léa Resende Moura - 2015.pdf: 2530978 bytes, checksum: 679a4f15f5a171aa51b27303b043b9b0 (MD5) license_rdf: 19874 bytes, checksum: 38cb62ef53e6f513db2fb7e337df6485 (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2016-04-20T15:27:01Z (GMT) No. of bitstreams: 2 Tese - Léa Resende Moura - 2015.pdf: 2530978 bytes, checksum: 679a4f15f5a171aa51b27303b043b9b0 (MD5) license_rdf: 19874 bytes, checksum: 38cb62ef53e6f513db2fb7e337df6485 (MD5) / Made available in DSpace on 2016-04-20T15:27:01Z (GMT). No. of bitstreams: 2 Tese - Léa Resende Moura - 2015.pdf: 2530978 bytes, checksum: 679a4f15f5a171aa51b27303b043b9b0 (MD5) license_rdf: 19874 bytes, checksum: 38cb62ef53e6f513db2fb7e337df6485 (MD5) Previous issue date: 2015-12-10 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / This study aimed to evaluate the effects of pequi shell etanolic extract (PSEE) (Caryocar brasiliense), through morphological evaluation and expression of MMP2, MMP9, TIMP1 and TIMP2 proteins in the myocardium of rats with experimental acute and chronic doxorubicin (DOX) cardiotoxicity, to better understand the mechanisms involved in this disease process. Thus, two experiments were carried out. In experiment groups of acute phase, 30 Wistar rats were divided in six groups of five animals each, being Sham group (SG) water and saline; (G1) 16 mg/kg DOX and treatment with 300 mg/kg of PSEE for 17 days; (G2) 16 mg/kg of DOX and 600 mg/kg of PSEE for 17 days; (G3) 16 mg/kg of DOX and 300 mg/kg of PSEE for 10 days; (G4) 16 mg/kg of DOX and 600 mg/kg of PSEE for 10 days; and (GC) 16 mg/kg DOX. Treatment of G1 and G2 began on day one and continued until the end of the experiment, on the 17th. G3 and G4 animals were treated with PSEE for ten days, from the day seven, and DOX was applied on the 14th day after the experiment beginning. Three days after the application of DOX, on the 17th, the animals were euthanized and macroscopic evaluation and collection of samples for enzymatic analysis, histopathology and immunohistochemistry were performed. In groups of the chronic phase experiment, 30 Wistar rats were divided in six groups of five animals. G1 and G2 received 300 mg/kg and 600 mg/kg of PSEE, respectively, as pretreatment, by gavage for seven days. In G1, G2, G3, G4 and control group (CG), cardiotoxicity was induced with weekly applications of 2 mg/kg DOX, intraperitoneally, totaling four applications (8 mg/kg), and Sham group (SG) received 1 ml saline solution. G3 animals received daily 300 mg/kg of PSEE and G4, 600 mg/kg, by gavage, for 21 days of application of DOX. The CG and SG received 1 ml of water daily by gavage also. After completion of the application animals were kept for two months, totaling three months of treatment. Macroscopic evaluation was performed by the 90 days and samples were taken for analysis in electron microscopy, histopathology and immunohistochemistry. In acute experiment was concluded that PSEE attenuates the the deleterious effects of the DOX on cardiac muscle undergoing acute drug-induced cardiotoxicity. When used at doses of 300 and 600 mg/kg for 17 days PSEE attenuates vacuolar degeneration in myocytes. When used at a dose of 600 mg/kg for 10 days PSEE reduces the fibers disruption. PSEE at a dose of 300 mg/kg for 17 days increases TIMP1 expression in the myocardium of rats treated with DOX. In chronic experiment was concluded that PSEE is effective in minimizing effects of chronic cardiotoxicity induced by DOX in the myocardium of rats, whereas at doses of 300 and 600 mg/kg, PSEE attenuates vacuolar degeneration in myocytes and at the dose of 600 mg/kg the PSEE reduces the amount of Anitschkow cells and myofibrils fragmentation. Keywords: Anthracycline, electron microscopy, histopathology / O presente estudo teve como objetivo avaliar a ação do extrato etanólico da casca do pequi (EECP) (Caryocar brasiliense), por meio de avaliação morfológica e expressão das proteínas MMP2, MMP9, TIMP1 e TIMP2, no miocárdio de ratos submetidos à cardiotoxicidade experimental aguda e crônica pela doxorrubicina (DOX), visando melhor entendimento dos mecanismos envolvidos nesse processo patológico. Para isso, foram realizados dois experimentos. Nos grupos do experimento de fase aguda, foram utilizados 30 ratos da raça Wistar, distribuídos em seis grupos de cinco animais cada, sendo grupo Sham (GS) água e solução salina; (G1) 16 mg/kg de DOX e tratamento com 300 mg/kg de EECP durante 17 dias; (G2) 16 mg/kg de DOX e 600 mg/kg de EECP durante 17 dias; (G3) 16 mg/kg de DOX e 300 mg/kg de EECP durante 10 dias; (G4) 16 mg/kg de DOX e 600 mg/kg de EECP durante 10 dias; e grupo controle (GC) 16 mg/kg de DOX. O tratamento de G1 e G2 teve início no dia um e estendeu-se até o término do experimento, no dia 17. Os animais de G3 e G4 foram submetidos a tratamento com EECP durante 10 dias, a partir do dia sete, e a DOX foi aplicada no 14° dia após o início do experimento. Três dias após a aplicação da DOX, no dia 17, os animais foram submetidos à eutanásia, avaliação macroscópica e colheita de amostras para análises histopatológica e imunoistoquímica. Nos grupos do experimento de fase crônica, foram utilizados 30 ratos da raça Wistar, distribuídos em seis grupos de cinco animais. G1 e G2 receberam como pré-tratamento com 300 mg/kg e 600 mg/kg de EECP, respectivamente, por gavagem, durante sete dias e mantiveram o tratamento durante os 21 dias de aplicação da DOX. Em G1, G2, G3, G4 e GC a cardiotoxicidade foi induzida com aplicações semanais de 2 mg/kg de DOX, via intraperitoneal, totalizando quatro aplicações (8 mg/kg) e, no GS foi aplicado 1 ml de solução fisiológica. Os animais de G3 receberam diariamente 300 mg/kg e os de G4 600 mg/kg de EECP, por gavagem, durante os 21 dias de aplicação da DOX. Os de GS e GC receberam 1 ml de água, diariamente, também por gavagem. Após o término das aplicações, os animais foram mantidos por dois meses em observação, totalizando três meses de experimento. A avaliação macroscópica foi realizada aos 90 dias, momento em que foram colhidas amostras para análise em microscopia eletrônica, histopatologia e imunoistoquímica. No experimento de fase aguda concluiu-se que o EECP minimiza os efeitos deletérios da DOX no miocárdio de ratos submetidos à cardiotoxicidade aguda induzida pelo fármaco. Quando utilizado nas doses de 300 e 600 mg/kg durante 17 dias o EECP atenua a degeneração vacuolar miocítica. Quando utilizado na dose de 600 mg/kg durante 10 dias o EECP reduz a desorganização das fibras. O EECP na dose de 300 mg/kg durante 17 dias aumenta a expressão de TIMP1 no miocárdio de ratos tratados com DOX. No experimento de fase crônica concluiu-se que o EECP é eficiente em minimizar os efeitos da cardiotoxicidade crônica induzida pela DOX no miocárdio de ratos, considerando que nas doses de 300 e 600 mg/kg, o EECP atenua a degeneração vacuolar miocítica e na dose de 600 mg/kg o EECP reduz a quantidade de células de Anitschkow e a fragmentação das miofibrilas.

Charles University in Prague Faculty of Pharmacy in Hradec Králové Department of Biochemical Sciences Candidate: Bc. Pavla Martinková Supervisor: PharmDr. Anna Jirkovská, PhD. Title of diploma thesis: Antiproliferative activity of novel dexrazoxane analogues and their effect on antitumor effectiveness of anthracyclines Athracycline antibiotics (such as daunorubicin, doxorubicin or epirubicin) belong to the most common terapeutics of both solid tumors and hematological malignities. Unfortunately the serious and life-threatening adverse effect cardiotoxicity compromises their clinical usefulness. The only approved protection against anthracycline cardiotoxicity so far is dexrazoxane. Despite the outstanding cardioprotective ability, dexrazoxane use is very limited mainly due to its possible side effects. So we were directed towards synthesis of dexrazoxane analogues with better pharmacological properties. The aim of this diploma thesis was to assess the antiproliferative activity of novel analogues of both dexrazoxane (MK-15 and ES-5) and ADR-925 (JR-159 and KH- TA4) and their influence on the antiproliferative effectiveness of anthracyclines. Moreover, we aimed to study their chelating properties and their inhibition of the topoisomerase II in solution. We tested the antiproliferative activity of...

Despite significant progress in the development of anti-cancer drugs, there is still a need for novel therapeutic strategies that would improve the outcome of cancer patients. Using proteomic technologies and cell lines with different phenotype of p53 tumour suppressor, we monitored cancer cell response to anti-cancer treatment with focus on the development of drug resistance. The different levels of metabolic proteins were identified in our study which may help to explain different anti-cancer activity of drugs with only a subtle difference in structure. More importantly, proteins associated with the development of drug resistance were identified and such expression changes have become a focus of interest. Our findings demonstrate a higher protein level of serine hydroxymethyltransferase, serpin B5 and calretinin in cancer cells resistant to Aurora kinase inhibitors. Such proteins promote the tumour growth with no apparent impact of p53 phenotype whilst voltage-dependent anion-selective channel protein 2 contributes to the development of resistance only in cells with functional p53 which is accompanied by the decreased level of elongation factor 2. On the other hand, cancer cells with loss of p53 appear to amplify alternative mechanisms such as protection against oxidative stress. The results...

La leucémie lymphoblastique aiguë (LLA) est le cancer le plus fréquent chez les enfants. Malgré le fait que plus de 80% des enfants atteints de LLA sont aujourd'hui guéris de leur maladie, ce succès a toutefois un prix élevé, car l’exposition aux médicaments cytotoxique et/ou à l’irradiation pendant une période vulnérable du développement de l’enfant peut entraîner des conséquences à long terme. En effet, environ 60% des enfants ayant survécu à une LLA devront vivre avec des problèmes de santé liés au traitement, également appelés effets indésirables tardifs (late-adverse effects, LAEs). Parmi ces derniers, on notera des problèmes métaboliques, l’ostéoporose, une altération des fonctions cognitives ou cardiaques, ainsi que la dépression et l’anxiété. Si certains survivants ne présentent aucune de ces complications, d'autres peuvent en avoir plusieurs. Différents facteurs peuvent contribuer à cette variabilité, notamment le traitement reçu, les caractéristiques de la maladie, les habitudes de vie et, surtout, la constitution génétique du patient. Ce projet s'est concentré sur les biomarqueurs génétiques permettant d'identifier les individus les plus susceptibles de souffrir de LAEs. Récemment, une étude exhaustive (évaluations cliniques, psychosociales et biochimiques) s’est déroulée au CHU Sainte-Justine pour caractériser chacune de ces morbidités chez 250 survivants de la LLA de l'enfant (cohorte PETALE). De plus, on a obtenu le profil génétique de chaque participant. Nous avons utilisé cet ensemble de données et des outils statistiques et bio-informatiques pour réaliser des études d'association comparant la fréquence des variants génétiques chez les survivants ayant développé ou non des LAEs; en particulier, les complications cardiovasculaires et neurocognitives, ainsi que les troubles de l'humeur tels que l'anxiété et la dépression. D'autres facteurs de risque tels que les caractéristiques de traitement et/ou de la leucémie ont été pris en compte lors de l'analyse pour dériver les meilleurs prédicteurs génétiques. Ainsi, en utilisant l'approche des gènes candidats, nous avons identifié les variants communs des gènes MTR, PPARA, ABCC3, CALML5, CACNB2 et PCDHB10 qui étaient associés à des déficits de performance des tests neurocognitifs, tandis que les variants des gènes SLCO1B1 et EPHA5 étaient associés à l'anxiété et à la dépression. Deux variants, rs1805087 dans le gène MTR et rs58225473 dans le gène CACNB2 sont particulièrement intéressants, car ces associations ont été validées dans la cohorte de réplication SJLIFE (St. Jude Children's Research Hospital, Memphis, USA). Les analyses d'association ont été complémentées par une étude d'association à l'échelle de l'exome, qui a identifié plusieurs gènes supplémentaires comme des modulateurs potentiels du risque de développer des complications neurocognitives liées au traitement (gènes AK8 et ZNF382), ainsi que l'anxiété et la dépression (gènes PTPRZ1, MUC16, TNRC6C-AS1, APOL2, C6orf165, EXO5, CYP2W1 et PCMTD1). Le variant rs61732180 du gène ZNF382 a ensuite été validé dans la cohorte de réplication SJLIFE. Également, nous avons effectué des analyses d’association concernant les complications cardiaques liées au traitement qui ont identifié plusieurs nouveaux marqueurs associés à ces complications dans les gènes TTN, NOS1, ABCG2, CBR1, ABCC5, AKR1C3, NOD2 et ZNF267. De plus, nous avons résumé les connaissances actuelles sur les marqueurs pharmacogénomiques qui ont été associés aux effets de cardiotoxicités, induites par les anthracyclines, qui affectent les patients atteints de cancer pédiatrique. Nous avons également inclus un aperçu de l'applicabilité des résultats rapportés, notamment ceux qui ont été validés dans la cohorte PETALE. Par ailleurs, nous nous sommes intéressés aux complications qui surviennent après une greffe de cellules souches hématopoïétiques. Nous avons appliqué des approches bio-informatiques et statistiques similaires pour obtenir un profil plus complet de la composante génétique derrière ces complications potentiellement mortelles. Ainsi, une étude d'association à l'échelle de l'exome a été réalisée dans une cohorte de patients pédiatriques subissant une greffe de cellules souches hématopoïétiques après un régime de conditionnement contenant du busulfan. Nous avons identifié de nouvelles variations génétiques conférant un risque plus élevé de syndrome d'obstruction sinusoïdale (notamment dans les gènes UGT2B10, BHLHE22, et KIAA1715) et de maladie aiguë du greffon contre l'hôte (dans les gènes ERC1, PLEK, NOP9 et SPRED1), qui pourraient être utiles pour des stratégies personnalisées de prévention et de traitement. Ces travaux contribuent à la compréhension de l'influence des facteurs génétiques sur le risque de développer des complications liées au traitement, tant au cours du traitement qu'à long terme. De plus, les marqueurs génétiques signalés ainsi que d'autres facteurs de risque connus peuvent conduire à des modèles de prédiction identifiant les patients à risque accru de ces complications. / Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Even though more than 80% of children with ALL are now cured of their disease, this success comes at a high price as exposure to cytotoxic drugs and/or radiation during a vulnerable period of child development may have long-term consequences. In fact, approximately 60% of children who survive ALL will have to live with treatment-related health problems, also called late-adverse effects (LAEs). These include metabolic problems, osteoporosis, impaired cardiac or cognitive functions, as well as depression and anxiety. While some survivors do not have any of these complications, others may have more than one. Different factors can contribute to this variability, in particular, the treatment received, the characteristics of the disease, the lifestyle, and, above all, the genetic makeup of the patient. This project focused on genetic biomarkers capable of identifying the individuals most likely to suffer from LAEs. Recently, an exhaustive study (clinical, psychosocial, and biochemical evaluations) took place at Sainte-Justine University Health Center (Montreal, Canada), with the goal to characterize each of these morbidities in 250 survivors of childhood ALL (PETALE cohort). In addition, the genetic profile of each participant was obtained, and we used statistical and bioinformatics tools to perform association studies on this dataset in order to compare the frequency of genetic variants in survivors with or without LAEs. We evaluated cardiovascular and neurocognitive complications, as well as mood disorders such as anxiety and depression. Other risk factors, such as treatment and/or leukemia characteristics were also considered during the analysis to derive the best genetic predictors. Thus, using the candidate gene approach, we identified common variants in the MTR, PPARA, ABCC3, CALML5, CACNB2, and PCDHB10 genes that were associated with deficits in neurocognitive tests performance, whereas variants in the SLCO1B1 and EPHA5 genes were associated with anxiety and depression. Two variants, rs1805087 in the MTR gene and rs58225473 in the CACNB2 gene, are of particular interest since these associations were validated in an independent SJLIFE replication cohort (St. Jude Children's Research Hospital, Memphis, USA). The association analyses were complemented by an exome-wide association study, which identified several additional genes as potential modulators of the risk of developing treatment-related neurocognitive complications (genes AK8 and ZNF382), as well as anxiety and depression (genes PTPRZ1, MUC16, TNRC6C-AS1, APOL2, C6orf165, EXO5, CYP2W1, and PCMTD1). Variant rs61732180 in the ZNF382 gene was further validated in the replication SJLIFE cohort. To a great extent, we performed association analyses regarding treatment-related cardiac complications which identified several novel markers associated with these toxicities in the TTN, NOS1, ABCG2, CBR1, ABCC5, AKR1C3, NOD2, and ZNF267 genes in survivors of childhood ALL. In addition, we summarized the current knowledge on pharmacogenomic markers related to anthracycline-induced cardiotoxicity affecting pediatric cancer patients. We also included a brief overview of the applicability of reported findings to the PETALE cohort, validating several of them. Besides, we were interested in the complications that arise after a hematopoietic stem cell transplantation. We applied similar bioinformatics and statistical approaches to gain a more complete insight into the genetic component behind these life-threatening complications. Thus, an exome-wide association study was performed in a cohort of pediatric patients undergoing hematopoietic stem cell transplantation following a conditioning regimen containing busulfan. Our results identified new genetic variations conferring a higher risk of sinusoidal obstruction syndrome (notably in the UGT2B10, BHLHE22, and KIAA1715 genes) and acute graft-versus-host disease (ERC1, PLEK, NOP9, and SPRED1 genes), which could be useful for personalized prevention and treatment strategies. This work contributes to the understanding of the influence of genetic factors on the risk of developing treatment-related complications, both during treatment and in the long term. Furthermore, the reported genetic markers along with other known risk factors can lead to prediction models identifying patients at increased risk for these complications.